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Background: Salbutamol and ipratropium bromide improve lung function in patients with 
chronic obstructive pulmonary disease (COPD). However, their bronchodilating effect has not 
yet been compared in the central and distal airways. Functional imaging using computational 
fluid dynamics offers the possibility of making such a comparison. The objective of this study 
was to assess the effects of salbutamol and ipratropium bromide on the geometry and compu-
tational fluid dynamics-based resistance of the central and distal airways.
Methods: Five patients with Global Initiative for Chronic Obstructive Lung Disease Stage III 
COPD were randomized to a single dose of salbutamol or ipratropium bromide in a crossover 
manner with a 1-week interval between treatments. Patients underwent lung function testing 
and a multislice computed tomography scan of the thorax that was used for functional imaging. 
Two hours after dosing, the patients again underwent lung function tests and repeat computed 
tomography.
Results: Lung function parameters, including forced expiratory volume in 1 second, vital capacity, 
overall airway resistance, and specific airway resistance, changed significantly after administra-
tion of each product. On functional imaging, the bronchodilating effect was greater in the distal 
airways, with a corresponding drop in airway resistance, compared with the central airways. 
Salbutamol and ipratropium bromide were equally effective at first glance when looking at lung 
function tests, but when viewed in more detail with functional imaging, hyporesponsiveness could 
be shown for salbutamol in one patient. Salbutamol was more effective in the other patients.
Conclusion: This pilot study gives an innovative insight into the modes of action of salbutamol 
and ipratropium bromide in patients with COPD, using the new techniques of functional imaging 
and computational fluid dynamics.
Keywords: chronic obstructive pulmonary disease, imaging, computed tomography, 
  computational fluid dynamics, salbutamol, ipratropium
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder character-
ized by dysfunction of the small and large airways, as well as destruction of the lung 
parenchyma and its vasculature, in highly variable combinations. The hallmark of COPD 
is limitation of expiratory flow, which is slowly progressive and irreversible.1,2
Small airway function is still mainly evaluated using specific lung function tests, 
including flow-volume loops, nitrogen washout, and helium flow volume loops.3 Recently, 
there has been a trend towards the identification of new outcome parameters to evaluate International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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lung function and treatment effects in COPD patients. In 
the literature, suggestions are made to investigate “volume 
parameters” like forced vital capacity after bronchodilation.4 
However, these spirometric tests have their limitations, in that 
they are effort-dependent, and the deep inspiration and forced 
expiration required alone can lead to changes in airway tone.5 It 
is known that bronchodilator drugs can improve lung mechan-
ics in COPD patients, despite little change in forced expira-
tory volume in 1 second (FEV1), by decreasing the amount of 
hyperinflation.6 Also, advanced imaging techniques based on 
multislice high-resolution computed tomography (CT) have 
been used to characterize COPD patients.7 These techniques 
allow for evaluation of the density of the parenchyma8 or for 
evaluation of airway lumen and wall thickness.9,10 Effects of 
bronchodilation on the bronchus-vessel ratio and airway lumen 
caliber have been studied in COPD patients by De Luca et al11 
and Hasegawa et al,12 respectively.
In recent years, a number of studies have used computa-
tional fluid dynamics to assess flow behavior in the respira-
tory system. The models used have been either idealized or 
based on realistic geometry,13–15 but very few studies have 
used image-based patient-specific models.16,17
Recent studies have indicated the possibility of using a 
combination of imaging tools and computer methods to pro-
vide functionality and to yield additional insight into clinically 
relevant issues, such as the bronchodilatory effects of inhaled 
medication. In the past, we have demonstrated a very good cor-
relation between spirometric indices like FEV1 and Tiffeneau 
index (FEV1/vital capacity, an index to discriminate between 
obstructive and restrictive pathology) and computational 
fluid dynamics-based calculation of overall and distal airway 
resistance, ie, from the segmental airways onwards. Therefore, 
functional imaging can be used to assess functional changes in 
the distal airways after pharmacological intervention. With this 
technique, it is possible to make a comparison of the broncho-
dilation induced by salbutamol (Ventolin™, GlaxoSmithKline, 
London, UK) versus ipratropium bromide (Atrovent® HFA, 
Boehringer Ingelheim, Ingelheim, Germany).
Salbutamol, a short-acting beta2-agonist, induces bron-
chodilation for up to 6 hours. It is used to treat wheezing, 
dyspnea, and breathing difficulties caused by asthma and 
COPD, to prevent bronchospasm during exercise, and to 
improve lung function.18
Ipratropium bromide is a short-acting anticholinergic 
bronchodilator (muscarinic antagonist) that induces bron-
chodilation for up to 6 hours. Beneficial effects include 
improvement in lung function, wheezing, dyspnea, and 
health-related quality of life in patients with COPD.18
Comparisons between salbutamol and ipratropium 
bromide have been previously performed but limited to spiro-
metric values and nonfunctional data, like dyspnea scores. 
In these studies, the degree of bronchodilation achieved with 
ipratropium bromide was equal to the degree of bronchodila-
tion achieved after using a short-acting beta2-agonist.19 Both 
compounds improve exercise capacity and reduce dyspnea 
to a similar extent.20 It is as yet unclear if salbutamol has 
a different effect at the level of the peripheral airways in 
comparison with ipratropium bromide.18
The aim of this study was to compare the effects of 
salbutamol and ipratropium bromide at the level of all air-
ways, especially in the distal and smaller airways. Recently 
developed functional imaging techniques offer the possibility 
to make these comparisons in detail and in a more sensitive 
way than is possible using the classical lung function tests. 
We compared these techniques in order to determine the 
most powerful method for assessment of bronchodilation 
in COPD.
Materials and methods
Patients
We recruited five patients with severe but stable COPD 
(three men and two women with Global Initiative for Chronic 
Obstructive Lung Disease [GOLD] Stage III disease). The 
degree of airway obstruction was verified by a baseline pul-
monary function test after at least 12 hours of bronchodilator 
withdrawal. Lung function testing was performed according 
to European Respiratory Society guidelines.21 The study pro-
tocol was approved by the local ethics committee and each 
patient gave informed consent to all procedures. Baseline 
patient characteristics are given in Table 1.
study design
The study was an open, randomized, two-way crossover, 
pilot study involving a screening visit and 2 study days 
Table 1 Baseline characteristics of the included patients with 
COPD
Mean ± SD Median Minimum Maximum
Age (years)   67.1 ± 5.4 65.6 61.6 76.2
FeV1 (L)   0.78 ± 0.14 0.81 0.60 0.93
VC (L)   2.38 ± 0.92 2.16 1.24 3.63
FeV1/VC (%) 35.40 ± 10.33 34.00 22.00 48.00
TLC (L)   6.63 ± 1.79 6.99 4.91 9.19
FrC (L)   5.11 ± 1.49 4.82 3.59 7.28
raw (kPa.s/L)   1.12 ± 0.17 1.04 1.00 1.41
Abbreviations: FeV1, forced expiratory volume in 1 second; VC, vital capacity; 
TLC, total lung capacity; sD, standard deviation; FrC, functional residual capacity.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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separated by at least 1 week to avoid any carryover effect. 
Prior to the first dosing, patients underwent lung function 
testing (spirometry, body plethysmography) and low-dose, 
high-resolution CT scanning of the thorax. After dosing, the 
patients once more underwent lung function tests and low-
dose, high-resolution CT scanning. These measurements 
were done 90 ± 30 minutes after the dose. The assessments 
on the second study day were the same as those done on the 
first day, except that the CT pre-dose was not taken to limit 
radiation exposure.
study medication
The study medications, salbutamol and ipratropium bro-
mide, were supplied by GlaxoSmithKline and Boehringer 
Ingelheim, respectively. The original medication and pack-
aging were used. At each visit, the patients received either 
four puffs of salbutamol 100 µg or four puffs of ipratropium 
bromide 20 µg. The medication was administered by the 
investigator or by a member of the clinical unit designated by 
the investigator. Patients were trained to use the devices.
After gentle expiration, a dose of salbutamol 100 µg or 
ipratropium bromide 20 µg was inhaled in one breath to 
total lung capacity from a valved spacer device. The breath 
was then held for 5–10 seconds before the subject exhaled. 
Four separate doses (total dose 400 µg of salbutamol or 
80 µg of ipratropium bromide) were delivered at 30-second 
intervals.
Inhaled corticosteroids were permitted during the study, 
provided that the dose remained constant for at least 6 weeks 
prior to the first visit and remained constant throughout the 
study period. An appropriate washout period for bronchodi-
lating products was determined to be at least 24 hours for 
long-acting bronchodilators and at least 6 hours for short-
acting bronchodilators prior to both study days.
CT and segmentation
High-resolution CT scans of the thorax can detect airways 
in the respiratory system down to the small airways with a 
diameter of 1–2 mm when imaged at total lung capacity.22–25 
From high-resolution CT images, patient-specific values can 
be derived for the lumen cross-sectional area, airway length, 
airway wall thickness, and the extent of emphysema. These 
values can be assessed either in a particular plane or by analyz-
ing multiple slices over a defined longitudinal region. These 
high-resolution CT scans enable three-dimensional recon-
struction of the airway geometry regions to be developed. 
This geometry reconstruction is performed by semiautomatic 
segmentation of the airways. This involves identification and 
grouping of voxels that belong to a specific anatomic structure, 
including the airway tree, the lungs or lobes or, in some cases, 
the fissures. A three-dimensional reconstruction of the mor-
phology can then be performed. Outcome parameters include 
lung volumes, lobar volumes, and local airway volumes. By 
assessing multiple scans of the same patient, it is possible to 
analyze the changes in different parameters either over time 
(eg, before and after bronchodilation), or at several breathing 
levels, such as forced residual capacity or total lung capacity. 
In this study, at each CT data collection time point, two CT 
thorax scans were taken on a 64-slice GE LightSpeed VCT 
scanner. One scan was taken at total lung capacity, the other 
at functional residual capacity. Lung volumes were controlled 
using adapted spirometry during the high-resolution CT 
procedure. Scans were taken in a dose reduction protocol, 
ie, reduced tube voltage (100 kV) and tube current as a func-
tion of patient weight (1 mAs/kg). In addition to this, there 
was an increase in noise factor to reduce the radiation dose 
further. Total radiation dose for the high-resolution CT scans 
taken in this study per patient was less than 12 mSv. Scanning 
time was less than 5 seconds per scan, voxel dimension was 
approximately 0.5 mm3, and the scanning region extended 
from the larynx down to the diaphragm.
From the high-resolution CT data, three-dimensional 
reconstruction of the airway geometry at total lung capacity 
was performed using semiautomatic segmentation of the 
airways up to the point where no distinction could be made 
between intraluminal and alveolar air (fifth to seventh bifurca-
tion, airway diameter approximately 1 mm). In addition, the 
lung lobes were segmented both at total lung capacity and 
functional residual capacity by identifying the fissure planes 
and subsequently using these surfaces as cutting objects. By 
segmenting the lung lobes at two lung levels it was possible to 
assess lobar expansion and hence the internal patient-specific 
mass flow distribution in the lower airways. The segmentation 
and three-dimensional model reconstruction was performed 
using a commercially developed and validated software pack-
age (Mimics®, Materialise, Leuven, Belgium). To determine 
the local change in airway volume, the models were subdi-
vided into individual branches according to the nomenclature 
defined by Ikeda (as described in Netter26). For each individual 
airway branch, the volume (iVaw) was determined before and 
after the administration of the medication.
Computational fluid dynamics
Functionality can be added to the static segmented images 
by applying computational fluid dynamics methods to 
  characterize airway resistance and aerosol deposition   patterns. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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The postprocessing involves airway wall smoothing and 
reduction of segmentation artifacts. The airway model is then 
converted into a computational grid using a commercial soft-
ware package (T-Grid®, Fluent Inc, Lebanon, NH) in order to 
solve the Navier-Stokes flow equations numerically. Flow is 
incompressible and isothermal, and most recent computational 
fluid dynamics models take into account the image-based 
internal flow distribution by including lobar expansion as a 
boundary condition. Computational fluid dynamics enables 
the determination of flow properties, including pressure, veloc-
ity, and density inside the entire flow domain. This allows the 
calculation of airway resistance by assessing the total pressure 
drop and airflow rate. Mesh size was around 4.5 × 106 cells. 
Steady flow simulations on these grids were performed using a 
commercial computational fluid dynamics solver (Fluent Inc). 
A mass flow of 30 L/minute was specified as the boundary 
condition at the trachea to reflect normal tidal breathing. At 
the outlets, the static pressure was defined using an iterative 
process to reflect the internal mass flow distribution matching 
the lobar expansion as derived from the CT data. The flow was 
considered laminar, incompressible, and adiabatic. Detailed 
descriptions of the segmentation and flow simulation proce-
dures can be found in De Backer et al.24
From the computational fluid dynamics data, the iRaw was 
obtained. iRaw was defined as:
iRaw =
∆p
F
where ∆p is the total pressure drop over a certain region and 
F is the mass flow rate of air through this region.
statistical analysis
Comparisons of airway characteristics before and after 
medication, as well as changes in airway characteristics 
between both medications, were assessed using the Wilcoxon 
matched-pairs test.
Comparisons between pulmonary function tests and func-
tional imaging were made using Spearman rank correlations. 
For all analyses, P , 0.05 was defined as statistically signifi-
cant and P , 0.1 as a trend. Analyses were performed using 
Statistica® software (StatSoft, Sandton, South Africa).
Results
All five patients completed the study. The patients (three male 
and two female, mean age 67 years) had GOLD Stage III 
COPD, a mean 71 pack-year smoking history, and an aver-
age FEV1 of 35% predicted (Tables 1 and 2). A detailed 
overview of the results and the abbreviations used can be 
found in Table 3 and Figures 1–3.
For these five patients, there was a significant increase 
in vital capacity (P = 0.04) and decrease in airway resis-
tance (Raw, P = 0.04) and specific resistance (sRaw, P = 0.04) 
1.5 hours after inhalation of salbutamol. Functional imag-
ing parameters showed an increase in total airway volume 
(iVawtot, P = 0.04) after salbutamol, with a small rise in iVawcentr 
(P = 0.08) and a large rise in iVawdist (P = 0.04). Also, after 
salbutamol, iRawtot decreased (P = 0.04) due to a reduction 
in iRawcentr (P = 0.08) and iRawdist (P = 0.08).
After ipratropium bromide, there was a rise in FEV1 
(P = 0.04) and a trend towards an increase in vital capac-
ity (P = 0.08), and a decrease in Raw (P = 0.08) and sRaw 
(P = 0.08). Functional imaging parameters show an increase 
in iVawtot (P = 0.04), with a small rise in iVawcentr (P = 0.04) 
and a large rise in iVawdist (P = 0.04). Also, after ipratropium 
bromide, iRawtot decreased (P = 0.04) due to a decrease in 
iRawcentr (P = 0.08) and iRawdist (P = 0.08).
No significant differences were found between changes 
in lung function testing and functional imaging parameters 
Table 2 Baseline lung function values in individual patients
Patient Age (years) FEV1 pre (%) FEV1 post-BD (%) FEV1 post-BD (L) VC (L) FEV1/VC TLC (L) FRC (L) Raw
1 66 31 35 0.73 1.95 34 7.14 5.87 1.04
2 65 34 34 0.91 2.16 43 4.92 4 1.12
3 76 31 37 0.71 1.24 48 4.91 3.59 1.409
4 65 25 33 1.07 3.63 22 9.19 7.28 1.02
5 61 33 36 0.98 2.92 30 6.99 4.82 1
Patient RV (L) IC (L)
1 5.19 1.35
2 2.76 1.01
3 3.67 1.04
4 5.55 1.92
5 4.07 1.73
Abbreviations: BD, bronchodilator; rFC, residual functional capacity; rV, residual volume; IC, inspiratory capacity; FeV1, forced expiratory volume in 1 second; TLC, total 
lung capacity; VC, vital capacity; raw, airway resistanceInternational Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 2 Changes in FeV1, VC, raw and sraw after salbutamol and ipratropium in five COPD patients (GOLD III). All changes are significant (P , 0.05) except the changes 
in FeV1 after salbutamol and VC after ipratropium.
Abbreviations: FeV1, forced expiratory volume in 1 second; VC, vital capacity; se, standard error; sD, standard deviation.
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after salbutamol or after ipratropium bromide. Looking at the 
functional imaging parameters, we noticed a trend towards a 
higher response to salbutamol. However, for one patient, we 
observed an inverse trend, with hyporeactivity to salbutamol. 
Repeating the statistical analysis without this hyporesponder 
to salbutamol, we obtain a trend in favor of salbutamol (com-
pared with ipratropium bromide) for the change in iVawtot 
(P = 0.07) and iRawtot (P = 0.07). Lung function testing did not 
detect any differences between salbutamol and ipratropium 
bromide. When we compared functional radiologic measure-
ments with classical lung function measurements (Tables 4 
and 5), we only found a significant Spearman rank correlation 
between resistance and Rtot. Functional imaging detects small 
differences and is more sensitive, which explains why these 
correlations are not strong.
Discussion
Using functional imaging, we demonstrated that central but 
mainly distal airway dimensions (third to seventh bifurcation) 
increased significantly after an inhaled beta2-agonist 
(salbutamol) and anticholinergic agent (ipratropium bromide) 
in patients with severe COPD. Corresponding changes in lung 
function (spirometry, airway resistance) could be observed, 
but the changes seen on lung function testing were overall 
less pronounced than the changes in airway caliber seen by 
the imaging method. The changes observed with imaging 
were even greater when airway resistance calculated using 
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Figure 3 Changes after salbutamol and ipratropium bromide in total (iVtot), central (iVcentr) and distal airway volume (iVdist) based on images of segmented airways and 
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Table 4 spearman rank comparison between functional imaging 
resistance and pulmonary function test (PFT) resistance
Rtot Rawcentr Rawdist
r (PFT) 0.52 0.17 -0.21
P 0.02 0.5 0.4
rspec (PFT) 0.27 -0.38 0.37
P 0.3 0.09 0.1
Abbreviations: rtot, total airway resistance; rawcentr, airway resistance in the central 
airways until third bifurcation; rawdist airway resistance of distal airways from third 
to seventh bifurcation.
computational fluid dynamics was taken into consideration. 
The latter method seems to provide added, more pronounced, 
and more sensitive information in the calculation of airway 
dimensions. Also, discrepancies between FEV1 and forced 
vital capacity responses were observed, with more pro-
nounced overall volume responses. Overall, the response to 
salbutamol was more pronounced than that to ipratropium 
bromide. However, ipratropium bromide was more active in 
one patient, especially when changes in airways caliber were 
taken into account.
Assessment of reversibility is recognized as an essential 
part of the management of airway obstruction.27 COPD 
patients are considered to have airflow limitation that is not 
fully reversible. While some patients can still show high 
reversibility, most COPD patients have limited changes 
in FEV1 after bronchodilators.28 Some can show larger 
changes in forced vital capacity and develop the so-called International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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volume response29 which is seen more in severe patients 
with end-expiratory flow limitation.4–30 We focused on the 
more common, severe COPD patients with little reversibil-
ity in FEV1 after bronchodilators. The functional imaging 
used in this study provided us with the opportunity to see 
whether changes in airway caliber and calculated airway 
resistance using computer methods were comparable with 
the limited changes seen in FEV1 in these patients. More-
over, the imaging method used provided information on 
changes in both central (until the third bifurcation) and dis-
tal (third to seventh bifurcation) airways. High-resolution 
CT has been used previously to determine bronchodilator 
responses either looking at changes in parenchymal den-
sity31 or at bronchus–vessel caliber relationship.11 Both 
methods are more indirect than the segmentation method 
used in this study complemented with computational fluid 
dynamics-based airway resistance measurements. We did 
not calculate emphysema scores for these patients, but we 
know from as yet unpublished data that functional imag-
ing can be of value in doing this, because we can measure 
blood vessel density in every lobe and compare this with 
the percentage of airflow going to this lobe. This way, we 
have an idea about the ventilation/perfusion match. We 
certainly have to include this technique in a larger study 
in the future.
The variable response to different bronchodilators in 
COPD patients has been observed before, and previous 
attempts to identify the right patients for certain products 
were not satisfying. Oga et al20 found that the effects of 
different bronchodilators on exercise capacity varied 
among individuals with stable COPD, while the degree of 
bronchodilation measured by FEV1 did not correlate with 
the increase in endurance time of the exercise test. This 
suggests that FEV1 is not an optimal descriptor of the bron-
chodilator effect. We did not measure diffusing capacity of 
the lung for carbon monoxide or maximum inspiratory and 
  expiratory pressure in this study, which could be interesting 
to compare in larger studies in the future, as would be the 
BODE index (we did not measure the 6-minute walking 
distance), because it is a global measure of COPD severity, 
which takes into account some important health-related 
quality of life measures.
We found that the response to salbutamol was larger in 
four out of five of our patients compared with the response 
to ipratropium bromide. However, a hyporesponse to salbu-
tamol was observed for one patient. Classical lung function 
testing was not able to make this distinction. FEV1 clearly 
underestimates the acute bronchodilator effects in COPD 
patients,32 probably because the main effect is situated in the 
distal airways, as we see with imaging.
In this study, we used functional imaging as a method 
for evaluating bronchodilator treatment in COPD. Because 
COPD is such a heterogeneous disease, the same treat-
ment does not have the same effect in different patients. 
This method helps us to understand why this is the case. 
It is the first method to evaluate regional resistances and 
volumes, and gives us new insights into the mechanism of 
bronchodilating treatment. It could help us to select the right 
treatment for the right patient, which should be the goal of 
every physician.
Suboptimal dosing may contribute to the wide varia-
tion of responders with different degrees of reversibility, 
because dose-response relationships have been demonstrat-
ed.33 Using higher doses, there is no substantial difference 
between using a short-acting beta-agonist or a short-acting 
muscarinic agonist. It has also been demonstrated that there 
is an effective improvement in FEV1 on adding a high dose 
of salbutamol (600 µg) or a high dose of ipratropium bro-
mide (120 µg) to regular tiotropium.34 A limitation of this 
study is the fact that we only studied patients with more 
severe GOLD Stage III COPD who are known to have more 
volume response. Additional insight could be gained by 
performing the same tests on patients with GOLD Stage I, 
II, and IV COPD.
Different descriptors of the disease, like genetics and 
emphysema scores, might also be of help in predicting 
response. Some studies have shown that genotype may 
determine the bronchodilating response.35,36 A larger study 
including all degrees of severity and performed over a lon-
ger time period could also give important information on 
the relationship between clinical outcomes (quality of life, 
dyspnea scores) and imaging data. We can conclude that 
salbutamol and ipratropium bromide have a bronchodilat-
ing effect in COPD patients, as indicated by a significant 
improvement in FEV1, vital capacity, Raw, and sRaw in 
Table 5 spearman rank comparison between change in pulmonary 
function test volumes and change in functional imaging volumes
ΔVtot ΔVcentr ΔVdist
∆rV (L) -0.32 -0.08 -0.29
P 0.04 0.8 0.4
∆rV (%) -0.46 -0.26 -0.39
P 0.2 0.5 0.3
∆FrC -0.46 -0.26 -0.39
P 0.2 0.5 0.3
Abbreviations: rV, residual volume; FrC, functional residual capacity; Vtot, total 
volume of the segmented airways; Vcentr, volume of the central airways until the 
third bifurcation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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classical lung function testing. Using functional imaging, 
regional differences in airway volumes and resistances can 
be detected after bronchodilation. Distal bronchodilation 
is more pronounced than central bronchodilation. iRawtot 
decreases, with a redistribution of airway resistance from 
the distal to the central airways. From classical lung func-
tion tests, there seems to be no difference in efficiency 
between salbutamol and ipratropium bromide. Neverthe-
less, using functional imaging parameters, we can distin-
guish two different types of responders, ie, the ones who 
respond more to salbutamol and a possible subgroup of 
hyporesponders to salbutamol. To confirm these findings, 
we need to study a larger group of patients, looking at 
different characteristics to predict and explain these dif-
ferent responses.
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